Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models.

@article{Lieber2013MineralocorticoidRA,
  title={Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models.},
  author={Gissela B Lieber and Xiomara Fern{\'a}ndez and Garfield G. Mingo and Yanlin Jia and Michael Caniga and Malgorzata A Gil and Shanil Keshwani and Janice D Woodhouse and Milenko Cicmil and Lily Y. Moy and Nancy H. Kelly and Johanna Jimenez and Yvette Crawley and John C. Anthes and Joel A. Klappenbach and Yu-Lu Ma and Robbie McLeod},
  journal={European journal of pharmacology},
  year={2013},
  volume={718 1-3},
  pages={
          290-8
        }
}
Accumulating evidence indicates protective actions of mineralocorticoid antagonists (MR antagonists) on cardiovascular pathology, which includes blunting vascular inflammation and myocardial fibrosis. We examined the anti-inflammatory and anti-fibrotic potential of MR antagonists in rodent respiratory models. In an ovalbumin allergic and challenged Brown Norway rat model, the total cell count in nasal lavage was 29,348 ± 5451, which was blocked by spironolactone (0.3-60 mg/kg, p.o.) and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Ang-(1-7) treatment attenuates lipopolysaccharide-induced early pulmonary fibrosis

Yongmei Cao, Yujing Liu, +5 authors Yanchu Li
  • Laboratory Investigation
  • 2019
VIEW 1 EXCERPT
CITES METHODS

Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.

  • Liver international : official journal of the International Association for the Study of the Liver
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND